Latest news with #LightDeliveryDevices
Business Wire
21-07-2025
- Business
- Business Wire
RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. ('RxSight' or 'the Company') (NASDAQ: RXST) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its financial results for the second quarter of 2025 on July 9, 2025. The Company reported declines in key metrics including sales of Light Delivery Devices ('LDD') along with a decline in total revenue across the organization. The Company also lowered its guidance for its full year financial performance, blaming the change in part on 'adoption challenges' that have caused an 'LDD stall.' Based on its financial performance, shares of RxSight fell by just under 38% on the same day. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
18-07-2025
- Business
- Business Wire
RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. ('RxSight' or 'the Company') (NASDAQ: RXST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its Q2 2025 financial results on July 9, 2025. The Company revealed declines in Light Delivery Devices ('LDD') sales and light adjustable intraocular lenses ('LAL') utilization, along with an overall revenue decline. The Company lowered its guidance for full year 2025, claiming that 'Adoption challenges over the last few quarters have been a primary reason for the LDD stall.' Based on this news, shares of RxSight fell by 37.8% on July 9, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
16-07-2025
- Business
- Business Wire
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of RxSight, Inc. ('RxSight' or the 'Company') (NASDAQ: RXST) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON RXSIGHT, INC. (RXST), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On July 9, 2025, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in Light Delivery Devices ('LDD') sales, light adjustable intraocular lenses ('LAL') utilization, and overall revenue. The Company also lowered its Full Year 2025 guidance by approximately $42.5 million at the midpoint and stated that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.' On this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq. Glancy Prongay & Murray LLP 1925 Century Park East, Suite 2100 Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding RxSight should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
15-07-2025
- Business
- Business Wire
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz continues its investigation of RxSight, Inc. ('RxSight' or the 'Company') (NASDAQ: RXST) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON RXSIGHT, INC. (RXST), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On July 9, 2025, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in Light Delivery Devices ('LDD') sales, light adjustable intraocular lenses ('LAL') utilization, and overall revenue. The Company also lowered its Full Year 2025 guidance by approximately $42.5 million at the midpoint and stated that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.' On this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, thereby injuring investors. Contact Us to Participate or Learn More: If you purchased RxSight securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
11-07-2025
- Business
- Business Wire
RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of RxSight, Inc. ('RxSight' or the 'Company') (NASDAQ: RXST) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RXSIGHT, INC. (RXST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 9, 2025, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in Light Delivery Devices ('LDD') sales, light adjustable intraocular lenses ('LAL') utilization, and overall revenue. The Company also lowered its Full Year 2025 guidance by approximately $42.5 million at the midpoint and stated that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall.' On this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025, thereby injuring investors. Contact Us to Participate or Learn More: If you purchased RxSight securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith 3070 Bristol Pike, Suite 112 Bensalem, Pennsylvania 19020 Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
